Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum of 77.50% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2025 was 75.00%, a 3.45% increase from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2024 was 72.50%, a 3.57% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum for fiscal 2023 was 70.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum 12 month |
|---|---|---|---|
| 2026-06-30 | 77.50% 10-Q · filed 2026-08-10 | ||
| 2025-12-31 | 75.00% 10-K · filed 2026-03-03 | ||
| 2024-12-31 | 72.50% 10-K · filed 2026-03-03 | ||
| 2023-12-31 | 70.00% 10-K · filed 2026-03-03 | ||
| 2023-09-30 | 70.00% 10-Q · filed 2024-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |